Nouscom, a clinical-stage biotechnology company developing cancer immunotherapies, has promoted Loredana Siani, Ph.D., to Chief Technology Officer following its recently announced €120 million ($135 million) Series D financing.
The appointment strengthens Nouscom’s leadership as the company prepares to advance NOUS-209, its lead investigational immunotherapy, into a registration-enabling clinical trial involving individuals with Lynch syndrome.
In her new role, Siani will oversee chemistry, manufacturing, and controls activities, commercial-scale manufacturing, and technical operations.
She will also continue leading the company’s technical organization as it prepares for more advanced clinical development and potential future commercialization.
Siani joined Nouscom in 2020 and most recently served as Senior Vice President, Technical CMC.
During her tenure, she helped establish manufacturing processes for Nouscom’s proprietary viral vector technologies.
The company’s manufacturing capabilities include large-scale production of off-the-shelf products and small-scale automated manufacturing for individualized immunotherapies.
These systems have supported clinical studies in North America and Europe.
Nouscom has also secured regulatory clearance for manufacturing processes and clinical trial materials associated with its programs.
Siani holds a Ph.D. in Industrial Biotechnology Science from the University Federico II in Naples and an executive MBA from Luiss Business School in Rome.
Alongside her promotion, Nouscom appointed Concetta Baldo as Head of Clinical Operations.
Baldo brings more than 15 years of experience in clinical research and operations and will lead global clinical development activities.
Nouscom’s NOUS-209 program focuses on cancer interception in individuals with Lynch syndrome, an inherited condition associated with increased risks of certain cancers.
The company’s broader pipeline includes therapies targeting microsatellite instability-high metastatic colorectal cancer and personalized neoantigen immunotherapies.
The executive appointments support Nouscom’s transition toward more advanced clinical trials and the development of commercial-scale manufacturing infrastructure.
KEY QUOTES:
“As Nouscom enters this important next phase, Loredana’s leadership and ability to execute will be critical. She has consistently demonstrated her deep technical expertise together with a solution-finding attitude, both in the GMP manufacturing and release of NOUS-209 and in our regulatory interactions for our forthcoming registration-enabling clinical trial. Together with her team, she has shaped and built our CMC, technical and manufacturing capabilities from the ground up. Successfully scaling a complex biologic from first clinical batches to commercial-scale manufacturing is often overlooked by biotech companies, but is as challenging and critical as generating clinical data. She and her team have always delivered.”
Marina Udier, Ph.D., CEO Of Nouscom
“Six years ago, I joined Nouscom with a single goal: to translate cutting-edge science into safe, scalable, and manufacturable medicines for patients. Over the years, I have learned that technology alone is not enough. What truly makes the difference is people, the quality of our decisions and our ability to execute with rigor when the stakes are high. I am deeply grateful to Marina for her trust, to the team with whom I have shared every challenge, and to our investors and partners for their continued support.”
Loredana Siani, Ph.D., Chief Technology Officer Of Nouscom
